Factors determining participation in prevention trials among systemic lupus erythematosus patients: A qualitative study

被引:46
作者
Costenbader, Karen H. [1 ]
Brome, Deborah [1 ]
Blanch, Danielle [1 ]
Gall, Victoria [1 ]
Karlson, Elizabeth [1 ]
Liang, Matthew H. [1 ]
机构
[1] Harvard Univ, Sch Med, Brigham & Womens Hosp, Boston, MA 02115 USA
来源
ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH | 2007年 / 57卷 / 01期
关键词
systemic lupus erythematosus; clinical trials; preferences; qualitative research; prevention; atherosclerosis;
D O I
10.1002/art.22480
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective. A feasibility study for a trial of strategies for the prevention of atherosclerosis in patients with systemic lupus erythematosus (SLE) was stopped because of inadequate recruitment. There is little understanding of the factors influencing patients' decisions about participation in prevention trials. Our goal was to determine factors that patients with SLE consider in deciding about participating in prevention trials, to uncover concerns about SLE trials, and to investigate how study design and purpose affect participation decisions. Methods. We conducted focus groups with trial participants (n = 13), trial nonparticipants (n = 8), and a group of patients with diabetes (n 9). We conducted telephone interviews with SLE patients who refused participation in the trial and the focus groups (n 10). A trained facilitator elicited factors influencing participation decisions. Transcripts were coded and grouped into themes using grounded theory. Results. Demographic characteristics of the groups were similar. Seven factors emerged as important in decision making: current health status, study design, physician involvement, personal benefit, altruism, time, and incentives. These factors were considered by individuals who elected to participate and those who did not, but weighed differently. Among the trial participants, good health status, encouragement from one's physician, and desires to learn and to contribute stimulated participation. Reasons for nonparticipation included current health status, medication and randomization concerns, and personal factors. Conclusion. We observed that similar factors were weighed differently by participants and nonparticipants. Our results suggest that strategies such as health education, enlistment of personal physicians, and limitation of time requirements may enhance recruitment of patients with SLE into clinical prevention trials.
引用
收藏
页码:49 / 55
页数:7
相关论文
共 20 条
  • [1] Epidemiology of cardiovascular disease in systemic lupus erythematosus
    Aranow, C
    Ginzler, EM
    [J]. LUPUS, 2000, 9 (03) : 166 - 169
  • [2] Bruce IN, 1998, CLIN EXP RHEUMATOL, V16, P435
  • [3] Barriers to a trial of atherosclerosis prevention in systemic lupus erythematosus
    Costenbader, KH
    Karlson, EW
    Gall, V
    De Pablo, P
    Finckh, A
    Lynch, M
    Bermas, B
    Schur, PH
    Liang, MH
    [J]. ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH, 2005, 53 (05): : 718 - 723
  • [4] Attitudes towards and participation in randomised clinical trials in oncology: A review of the literature
    Ellis, PM
    [J]. ANNALS OF ONCOLOGY, 2000, 11 (08) : 939 - 945
  • [5] Recruitment strategies in superiority trials in SLE: lessons from the study of methotrexate in lupus erythematosus (SMILE)
    Ferland, D
    Fortin, PR
    [J]. LUPUS, 1999, 8 (08) : 606 - 611
  • [6] Risk-attitude and patient treatment preferences
    Fraenkel, L
    Bogardus, ST
    Wittink, DR
    [J]. LUPUS, 2003, 12 (05) : 370 - 376
  • [7] Glaser BG., 1998, DOING GROUNDED THEOR
  • [8] Clinical trial enrollers vs nonenrollers: The cardiac arrhythmia suppression trial (CAST) recruitment and enrollment assessment in clinical trials (REACT) project
    Gorkin, L
    Schron, EB
    Handshaw, K
    Shea, S
    Kinney, MR
    Branyon, M
    Campion, J
    Bigger, JT
    Sylvia, SC
    Duggan, J
    Stylianou, M
    Lancaster, S
    Ahern, DK
    Follick, MJ
    [J]. CONTROLLED CLINICAL TRIALS, 1996, 17 (01): : 46 - 59
  • [9] Patterns of patient enrollment in randomized controlled trials
    Haidich, AB
    Ioannidis, JPA
    [J]. JOURNAL OF CLINICAL EPIDEMIOLOGY, 2001, 54 (09) : 877 - 883
  • [10] How accelerated atherosclerosis in SLE has changed our management of the disorder
    Hallegua, DS
    Wallace, DJ
    [J]. LUPUS, 2000, 9 (03) : 228 - 231